Axsome Therapeutics (AXSM) had the highest return in March 2019 by a mid-cap US stock, returning 78.5%.
| ASSET | MONTH | % RETURN |
|---|---|---|
Axsome Therapeutics (AXSM) | March 2019 | 78.54% |
Catalyst Pharmaceuticals (CPRX) | March 2019 | 74.06% |
Alphatec (ATEC) | March 2019 | 65.63% |
Protagonist Therapeutics (PTGX) | March 2019 | 56.54% |
Skeena Resources (SKE) | March 2019 | 43.67% |
Krystal Biotech (KRYS) | March 2019 | 43.11% |
Immunitybio (IBRX) | March 2019 | 38.6% |
Levi Strauss & Co Class A (LEVI) | March 2019 | 38.53% |
Soleno Therapeutics (SLNO) | March 2019 | 36.42% |
Acm Research (ACMR) | March 2019 | 34.17% |
Plug Power (PLUG) | March 2019 | 33.33% |
StoneCo (STNE) | March 2019 | 33.04% |
OneSpaWorld (OSW) | March 2019 | 32.75% |
ELF Beauty (ELF) | March 2019 | 32.5% |
Apellis Pharmaceuticals (APLS) | March 2019 | 27.45% |
Merus (MRUS) | March 2019 | 25.7% |
Torm PLC Class A (TRMD) | March 2019 | 25.21% |
YETI (YETI) | March 2019 | 24.9% |
Veracyte (VCYT) | March 2019 | 23.25% |
Rev (REVG) | March 2019 | 22.76% |
Abercrombie & Fitch (ANF) | March 2019 | 22.23% |
CLARIVATE (CLVT) | March 2019 | 22.18% |
TransAlta (TAC) | March 2019 | 21.32% |
TG Therapeutics (TGTX) | March 2019 | 20.36% |
ConAgra Foods (CAG) | March 2019 | 18.45% |
Mid-cap stocks are treated as having a market cap between $2B and $10B.
